|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Electrical storm: A clinical and electrophysiological overview显示文摘Electrical storm(ES) is a clinical condition characterized by three or more ventricular arrhythmia episodes leading to appropriate implantable cardioverterdefibrillator(ICD) therapies in a 24 h period. Mostly, arrhythmias responsible of ES are multiple morphologies of monomorphic ventricular tachycardia(VT), but polymorphic VT and ventricular fibrillation can also result in ES. Clinical presentation is very dramatic in most cases, strictly related to the cardiac disease that may worsen electrical and hemodynamic decompensation. Therefore ES management is challenging in the majority of cases and a high mortality is the rule both in the acute and in the long-term phases. Different underlying cardiomyopathies provide significant clues into the mechanism of ES, which can arise in the setting of structural arrhythmogenic cardiomyopathies or rarely in patients with inherited arrhythmic syndrome, impacting on pharmacological treatment, on ICD programming, and on the opportunity to apply strategies of catheter ablation. This latter has become a pivotal form of treatment due to its high efficacy in modifying the arrhythmogenic substrate and in achieving rhythm stability, aiming at reducing recurrences of ventricular arrhythmia and at improving overall survival. In this review, the most relevant epidemiological and clinical aspects of ES, with regard to the acute and long-term follow-up implications, were evaluated, focusing on these novel therapeutic strategies of treatment. | Sergio Conti Salvatore Pala Viviana Biagioli Giuseppe Del Giorno Martina Zucchetti Eleonora Russo Vittoria Marino Antonio Dello Russo Michela Casella Francesca Pizzamiglio Valentina Catto Claudio Tondo Corrado Carbucicchio | 2015 | World Journal of Cardiology2015，7，9： | 9 |
| 2 | Gastric cancer in the elderly 显示文摘 | Zucchetti F Negro F Matera D | 2001 | Ann Ital Chir2001，72，2： | 1 |
| 3 | Galectin-3,a marker of well differentiated thyroid carcinoma is expressed in thyroid nodules with cytological a typia显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathol- ogy2002，40，1： | 1 |
| 4 | Galectin-3,a marker of well-differentiated thyroid carcinoma,is expressed in thyroid nodules with cytological atypia显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 5 | A first in human phase 1 study of the proteasome inhibitor CEP - 18770 in patients with advanced solid tumours and multiple myeloma 显示文摘 | Gallerani E Zucchetti M Brunelli D | 2013 | Eur J Cancer2013，49，2： | 1 |
| 6 | Galectin-3,a markerof well differentiated thyroid carcinoma is expressed in thyroidnodules with cytological atypia显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 7 | Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivatives 显示文摘 | Pagani O Zucchetti M Sessa C | 1996 | Cancer Chemother Pharmacol1996，38，： | 1 |
| 8 | Role of Macrophage Targeting in the Antitumor Activity of Trabectedin显示文摘 | Giovanni Germano Roberta Frapolli Cristina Belgiovine Achille Anselmo Samantha Pesce Manuela Liguori Eugenio Erba Sarah Uboldi Massimo Zucchetti Fabio Pasqualini Manuela Nebuloni Nico van Rooijen Roberta Mortarini Luca Beltrame Sergio Marchini Ilaria Fuso | 2013 | Cancer Cell2013，，2： | 1 |
| 9 | Galectin-3, a marker of well-differentianted thyroid carcinoma, is expressed in thyroid nodules with cytological atypia显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | 40(1) :80-872002，40，1： | 1 |
| 10 | Galectin-3,a marker of well differentiated thyroid carcinoma,is expressed in thyroid nodules with cytological atypia显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 11 | Galectin-3,a marker of well-differentiated thyroid carcinoma,is expressed in thyroid nodules with cytological atypia显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 12 | Galectin-3, a marker of welldifferentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia 显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 13 | Galectin-3,a marker of well differentiated thyroid carcinoma is expressed in thyroid nodules with cytological atypia显示文摘 | Coli A BigottiG Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 14 | Do Anticancer Agents Reach the Tumor Target in the Human Brain?显示文摘 | Donelli M G Zucchetti M D'Incalci M | 1992 | Cancer Chemother Pharmacol1992，30，： | 1 |
| 15 | Galectin-3, a marker of welldifferentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia 显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 16 | Galectin-3,a marker of well differentiated thyroid carcinoma is expressed in thyroid nodules with cytological atypical显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 17 | Galectin-3, a marker of well- differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia显示文摘 | Coli A Bigotti G Zucchetti F | 2002 | Histopathology2002，40，1： | 1 |
| 18 | Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials显示文摘 | Ghassan M. Sulaiman Khulood W. Al Sammarrae Ali H. Ad’hiah Massimo Zucchetti Roberta Frapolli Ezia Bello Eugenio Erba Maurizio D’Incalci Renzo Bagnati | 2011 | Food and Chemical Toxicology2011，，9： | 1 |
| 19 | Galectin-3,a marker of well differentiated thyroid carcinoma,is expressed in thyroid nodules with cytological atypia显示文摘 | COLI A BIGOTTI G ZUCCHETTI F | 2002 | Histopathology2002，40，1： | 1 |
| 20 | A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia显示文摘 | Rizzari C Citterio M Zucchetti M | 2006 | Haematologica2006，91，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员